Rechercher des projets européens

21 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma (EEC)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Ewing Sarcomas (ES) are fatal, rare bone cancers particularly affecting young people. About 60% of patients achieve long term survival with current treatment but there has been no improvement in this proportion for 25 years. Treatment is unsuccessful because chemotherapy fails to prevent the development of, or to effectively treat established, metastases. In addition, of the 600 new cases of ES o ...
Voir le projet

 21

 TERMINÉ 

Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington’s disease (Repair-HD)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

This project will tackle the huge complexity of taking stem cell therapies to clinical application for neurodegenerative disease by focusing on selective differentiation of a single neuronal phenotype (medium spiny striatal neuron: MSN) for a single well-defined disease (Huntington’s: HD). Our consortium contains expertise in all elements required to drive this technology to the point of clinical ...
Voir le projet

 10

 TERMINÉ 

Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases (D-BOARD)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

"Chronic inflammatory diseases of joints are major causes of disability in the ageing population. Osteoarthritis (OA) is one of the most common types of arthritis and a major cause of pain and disability in older individuals. OA is expected to place a heavy burden on European healthcare systems, as European citizens grow older. Cartilage damage in OA is detected radiographically by decreases in jo ...
Voir le projet

 15

 TERMINÉ 

Clinical European study on the outcome of surgical and hormonal therapy and psychological intervention in disorders of sex development (DSD) (DSD-LIFE)

Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,

Disorders of sex development (DSD) are a conglomerate of rare diseases with an estimated incidence of 1: 4500. The causes of DSD are mainly disorders with gonadal dysgenesis, decreased androgen synthesis or function in XY males or disorders with elevated androgen production in XX females. Decision on sex of rearing is difficult in some cases as the prenatal androgen imbalances result in ambiguous ...
Voir le projet

 17

 TERMINÉ 

MId- to NEaR infrared spectroscopy for improVed medical diAgnostics (MINERVA)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,

In recent years it has become clear that mid-IR imaging spectroscopy has the potential to open a new chapter in bio-medical imaging and offers an effective tool for early cancer diagnosis and improved survival rates. Rather than a search for "cancer marker" absorption peaks, great progress has been made by analysing the entire bio-molecular mid-IR spectral signature using automated algorithms. How ...
Voir le projet

 14

 TERMINÉ 

Best EScalation Treatment in Multiple Sclerosis (MS) (BEST MS)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,

"Multiple Sclerosis (MS) is a devastating disease of the central nervous system affecting 2.5 million worldwide. MS is a field of constant therapeutic innovation, a fact which brings hope to young adults since MS is one of the most frequent causes of severe handicap. A major unmet need is to rationalize treatment decisions. To date, there is no way of predicting which patients will best respond to ...
Voir le projet

 5

 TERMINÉ 

ANTIcipating the Global Onset of Novel Epidemics (ANTIGONE)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2016,

In recent years, an increased number of zoonotic viruses and bacteria have crossed the species barrier to humans and caused or threatened to cause human pandemics with high morbidity and mortality. Because of our inability to predict the emergence of these pathogens, it is difficult to take preventive measures. It is known that zoonotic pathogens need to cross barriers at the animal-human interfac ...
Voir le projet

 14

 TERMINÉ 

Cancer Associated Fibroblasts (CAF) Function in Tumor Expansion and Invasion (CAFFEIN)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,

"Aim of the CAFFEIN network is to provide 10 early stage researchers (ESRs) and 2 exprerienced researchers (ERs) with excellent training in an industry relevant area of cancer research, complementary skills required for pharmaceutical industry, and knowledge in setting up biomedical start-up companies. To this end, the network comprises two full industrial partners: the established pharmaceutical ...
Voir le projet

 11

 TERMINÉ 

Next Generation Genome Based High Resolution Tracing of Pathogens (PathoNgen-Trace)

Date du début: 1 janv. 2012, Date de fin: 30 juin 2016,

"Next generation sequencing (NGS) has fundamentally altered genomic research. New developments will bring NGS costs and performance down to an everybody's technology with extreme potential for ultra fast and accurate molecular typing and diagnostic as it provides the ultimate whole genome information. However, technical and bioinformatics constraints, restrict the application of NGS to few highly ...
Voir le projet

 8

 TERMINÉ 

Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia (BESTCILIA)

Date du début: 1 déc. 2012, Date de fin: 31 mai 2016,

Primary Ciliary Dyskinesia (PCD) is a rare genetically heterogeneous disorder which results from dysfunction of motile hair-like organelles (cilia) that results in severe, chronic airways disease. Due to other cilia-related disease mechanisms several other organ systems like the heart can be affected. The complexity of the disease phenotype, late diagnosis, as well as lack of evidence based manage ...
Voir le projet

 12

 TERMINÉ 

EUropean TRanslational training for Autoimmunity & Immune manipulation Network (EUTRAIN)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,

Immune-mediated inflammatory diseases (IMID) are important health challenges in Europe and beyond, afflicting an estimated 5-8% of the total population. IMID with an onset during childhood such as Juvenile Idiopathic Arthritis (JIA) cause particular concern as pediatric patients form an especially vulnerable group. Currently there is no safe and cost-effective cure for JIA and related juvenile IMI ...
Voir le projet

 11

 TERMINÉ 

Managing Risks of Nanoparticles (MARINA)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

While there are standard procedures for product life cycle analysis, exposure, hazard, and risk assessment for traditional chemicals, is not yet clear how these procedures need to be modified to address all the novel properties of nanomaterials. There is a need to develop specific reference methods for all the main steps in managing the potential risk of ENM. The aim of MARINA is to develop such ...
Voir le projet

 54

 TERMINÉ 

Emotional learning and extinction: integration of central and peripheral neural correlates (EMOLEARN)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

With a life-time prevalence of 25%, anxiety disorders are the most frequent psychiatric disorders and alone accounted for 147 billion Euros EU health care costs in 2004.The aim of this Marie Curie collaborative research project is to combine and share scientific expertise and shed more light on the dysfunctional neurocircuitry of anxiety disorders.Our current understanding has largely benefited fr ...
Voir le projet

 2

 TERMINÉ 

Ion Transport Proteins in Control of Cancer Cell Behaviour (IonTraC)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2015,

"With over 3 million new cases and 1.5 million arising deaths each year in Europe, cancer is a major public health problem with an urgent need for new therapies. This proposal builds upon mounting evidence that ion channels and transporters underlie many of the hallmarks of cancer. Thus, proteins involved in membrane transport, long known as important drug targets in other pathologies (channelopat ...
Voir le projet

 11

 TERMINÉ 

European Primate Network: Advancing 3Rs and International Standards in Biological and Biomedical Research (EUPRIM-NET II)

Date du début: 1 janv. 2011, Date de fin: 30 juin 2015,

Biomedical research depends on the availability of living non-human primates and biological material with primate origin. The need for animal research using non-human primates is therefore recognised by all governments that support internationally competitive biomedical research aimed at addressing the world’s most pressing medical challenges. While essential for biomedical research owing to their ...
Voir le projet

 13

 TERMINÉ 

A systems biology approach to dissect cilia function and its disruption in human genetic disease (SYSCILIA)

Date du début: 1 juin 2010, Date de fin: 31 mai 2015,

AIM: To identify the molecular mechanisms characterizing cilium function, and the discrete perturbations associated with dysfunction caused by mutations in inherited ciliopathies, applying a systems biology approach. BACKGROUND: Cilia are microtubule-based, centriole-derived projections from the cell surface. They transduce extracellular signals and regulate key processes in which signals of the e ...
Voir le projet

 17

 TERMINÉ 

Long-term PHARMacovigilance for Adverse effects in Childhood arthritis focussing on Immune modulatory drugs (PHARMACHILD)

Date du début: 1 avr. 2011, Date de fin: 30 sept. 2014,

Until the age of biotechnology, treatment options for children and adolescents with severe arthritis, inflammatory bowel diseases and other serious diseases with chronic inflammation were limited. Advances in understanding the pathophysiology of the inflammatory responses have led to the development of a new class of medications that are capable of inhibiting selectively the principal mediators of ...
Voir le projet

 9

 TERMINÉ 

Similarities and differences between neural stem cells and cancer stem cells (Cancer stem cells)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2012,

Not all cancer cells are born equal. It could be demonstrated that tumors are formed by different cell types, mostly exhibiting a limited potential of proliferation. Further, it was shown that malignant tumor behaviour is fuelled by a minority of key-players harbouring the ability to form new tumors after transplantation. Such tumor founding cells share multiple characteristics with stem cells, an ...
Voir le projet

 1

 TERMINÉ 

Lipid droplets as dynamic organelles of fat deposition and release: Translational research towards human disease (LipidomicNet)

Date du début: 1 mai 2008, Date de fin: 31 oct. 2012,

Lipids are central to the regulation and control of cellular processes by acting as basic building units for biomembranes, the platforms for the vast majority of cellular functions. Recent developments in lipid mass spectrometry have set the scene for a completely new way to understand the composition of membranes, cells and tissues in space and time by allowing the precise identification and quan ...
Voir le projet

 27

 TERMINÉ 

Network of Excellence for Biophotonics (PHOTONICS4LIFE)

Date du début: 1 mai 2008, Date de fin: 30 juin 2012,

Today Biophotonics is an emerging multidisciplinary research area, embracing all light-based technologies applied to the life sciences and medicine. Enhancing diagnosis, therapy and follow-up care, Biophotonics drives the trend towards personalized medicine and plays a crucial role in limiting health-care costs and appropriately addressing the accelerating challenges associated with population agi ...
Voir le projet

 15

 TERMINÉ 

Virtual Pathological Heart of the Virtual Physiological Human (VPH2)

Date du début: 1 juil. 2008, Date de fin: 31 oct. 2011,

Heart failure accounts for almost a quarter of all admissions to hospital for cardiovascular events, has a high mortality (median survival around 18 months), and places a great burden on all healthcare systems, with estimated direct costs of £905m (?1350m) in the United Kingdom in 2000, 2% of total NHS expenditure.VPH2 aims to develop a patient-specific computational modelling and simulation of th ...
Voir le projet

 17